news flash relenza quarterly sales

Second Quarter Sales - Lower as expected

Sales: AUD6.2

Royalty: $0.4m

Change to last Quarter:

Commentary: Sales of Relenza, an anti-viral treatment for influenza were lower than the comparative quarter of 2007 at
£3 million, reflecting the variable timings of tender orders from governments.

Other: With respect to the complaint filed by Biota Holdings Limited in the Victorian Supreme Court in Australia
alleging that the Group had failed to fulfil its obligations for Relenza (zanamivir), the parties held a mediation
meeting on the 17th and 18th July and reached agreement on a settlement. Under the terms of the settlement,
GSK admits no liability but will make a payment of AUD 20 million (£10 million) to Biota.